Abstract:Blood-based liquid biopsies enable non-invasive characterization of cancers. Cell-free RNA (cfRNA) analysis could potentially complement circulating tumor DNA (ctDNA) analysis and allow broader molecular characterization of cancers but has not been extensively explored. Here, we describe RARE-Seq, a novel cfRNA sequencing method designed to maximize sensitivity by targeting rare, tissue-specific transcripts, and simultaneously detecting both tumor-derived expression signatures and somatic mutations in circulating tumor RNA (ctRNA). To interrogate samples for specific gene expression signatures, we developed and optimized a framework to measure tumor- and tissue-specific enrichment scores (ES) within cfRNA. We then empirically determined the limit of detection (LOD95) of RARE-Seq using admixtures of tumor cell line RNA and control cfRNA across a wide range of fractions. We found RARE-Seq to have an estimated LOD95 of 0.05% for cancer-derived RNA, which was 52-fold better than whole transcriptome cfRNA profiling. To explore its potential clinical utility, we profiled 192 samples from 170 subjects with various cancers and non-cancer controls using RARE-Seq. Non-small cell lung cancer (NSCLC) expression signatures were significantly detected in 40 out of 51 NSCLC samples (78% sensitivity at 90% specificity). Detection increased with stage, ranging from 40% in stage I to 87% in stage IV. In a subset of stage IV NSCLC patients with matching ctDNA data (n=16), ctRNA levels were significantly correlated with ctDNA allele frequencies (Pearson R=0.84, P=0.005). Intriguingly, 86% of samples with undetectable ctDNA contained detectable ctRNA, suggesting potential complementarity of ctRNA and ctDNA analysis for cancer detection. We also developed and benchmarked a direct ctRNA genotyping approach, allowing noninvasive detection of driver mutations in 42% of patients with advanced NSCLC. When applied to other tumors, RARE-Seq demonstrated 80-100% sensitivity at 90% specificity for detection of pancreatic adenocarcinomas (PAAD), prostate adenocarcinomas (PRAD), and hepatocellular carcinomas (LIHC). Furthermore, when evaluating tissue of origin (TOO) classification performance, RARE-Seq achieved 85% median accuracy for the top predicted tissue and 96% median accuracy for the top two tissues. These results highlight the potential value of ultrasensitive cfRNA analysis, providing proof-of-principle for detection of multiple tumor types using RARE-Seq. Citation Format: Monica C. Nesselbush, Bogdan A. Luca, Young-Jun Jeon, Isabel Jabara, Catherine B. Meador, Michael S. Binkley, Nova Xu, Angela B. Hui, Andrea Garofalo, William Y. Shi, Kevin J. Liu, Takeshi Sugio, Noah Kastelowitz, Emily G. Hamilton, Rene F. Bonilla, Yi Peng Wang, Alice Jiang, Brianna Lau, Jordan Eichholz, Mandeep Banwait, Joseph Schroers-Martin, Jan Boegeholz, Daniel A. King, Mohammad S. Esfahani, Tyler Raclin, Robert Tibshirani, Sandy Srinivas, Viswam S. Nair, James M. Isbell, Bob T. Li, Zofia Piotrowska, Lecia V. Sequist, Aaron N. Hata, Joel W. Neal, Heather A. Wakelee, Andrew J. Gentles, Ash A. Alizadeh, Maximilian Diehn. Cell-free RNA analysis for non-invasive cancer detection and characterization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6560.

Critical assay parameters facilitating confident detection of expression changes, fusions and short variants in RNA isolated from tissue

RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.

Clinical Implementation of RNA Signatures for Pharmacogenomic Decision-Making.

Impact of RNA-seq data analysis algorithms on gene expression estimation and downstream prediction

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing

Abstract 465: Development and validation of a targeted RNA-Seq assay for gene fusion detection and expression quantification in FFPE samples

Abstract 6560: Cell-free RNA analysis for non-invasive cancer detection and characterization

Comprehensive Assessments of RNA-seq by the SEQC Consortium: FDA-Led Efforts Advance Precision Medicine

RNA-Seq Analysis in Non-Small Cell Lung Cancer: What Is the Best Sample from Clinical Practice?

Toward Best Practice in Identifying Subtle Differential Expression with RNA-seq: A Real-World Multi-Center Benchmarking Study Using Quartet and MAQC Reference Materials

A Real-World Multi-Center RNA-seq Benchmarking Study Using the Quartet and MAQC Reference Materials

Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction.

Tissue Handling and Specimen Preparation in Surgical Pathology: Issues Concerning the Recovery of Nucleic Acids From Formalin-Fixed, Paraffin-Embedded Tissue

SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA

A New Approach of Detecting ALK Fusion Oncogenes by RNA Sequencing Exon Coverage Analysis

RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies

Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology

Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in Nonsmall Cell Lung Cancer

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network

Quality assurance of RNA expression profiling in clinical laboratories